Nuvation Bio vs Puma Biotechnology
NUVB and PBYI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NUVB and PBYI compare
Nuvation Bio is the larger company, worth 3.5 times as much as Puma Biotechnology ($1.4B against $401M).
Nuvation Bio grew revenue faster over the last twelve months (654% versus 9.4% for Puma Biotechnology).
Puma Biotechnology keeps more of each dollar of sales as profit, with a net margin of 10.3% compared with −67.4% at Nuvation Bio.
Puma Biotechnology scores higher on the StockData Score (14 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NUVB | PBYI |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $401M |
| Share price | $3.99 | $7.77 |
| Change, 1 year | −19.1% | 55.7% |
| Change, 5 years | −55.9% | 127% |
| Beta (5Y) | 1.45 | 0.97 |
| Employees | 298 | 179 |
| StockData Score | ||
| Total score | 4 | 14 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 | 5 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 16.9× |
| P/S | 6.9× | 1.7× (better) |
| P/B | 6.1× | 2.7× (better) |
| EV/EBITDA | – | 8.3× |
| P/FCF | – | 8.7× |
| FCF yield | – | 11.5% |
| Fair value | $1.94 | $8.76 |
| Margin of safety | −105% | 11.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 654% (better) | 9.4% |
| Revenue growth, 5Y average | – | 0.29% |
| Net income growth (TTM) | – | −35.6% |
| EPS growth (TTM) | – | −37.8% |
| Profitability | ||
| Gross margin | – | 73.6% |
| Operating margin | −61.2% | 11.3% (better) |
| Net margin | −67.4% | 10.3% (better) |
| FCF margin | – | 19.9% |
| Return on equity | −49.1% | 18.2% (better) |
| Return on invested capital | – | 38.7% |
| Financial health | ||
| Debt / equity | 0.03 (better) | 0.00 |
| Net debt / EBITDA | – | −2.77 |
| Interest coverage | −5.9× | 12.9× (better) |
| Current ratio | 7.45 (better) | 3.03 |
| Altman Z-score | 0.06 (better) | −2.31 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 74.9% |
| Held by insiders | 24.6% | 18.9% |
| Insider net buying, 12 months | −$4.5M | −$2.0M (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 23.4% | 10.3% |
Go deeper
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
- PBYI stock overview
- PBYI income statement
- PBYI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.